Evidence map›Paper›PMID 42486095›Full record

Trial reportCell reports. Medicine2026

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Liang Zeng, Fang Tian, Cunji Wang, Qun Chen, Wenjuan Jiang, Juan Liang, Yanming Tan, Huan Yan, Jiao Huang, Chunhua Zhou and 16 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05001971 (Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05001971 phase2completednot on this map

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy: a Single-arm, Multicenter Pilot Study

TypeinterventionalSponsorHunan Cancer HospitalRan2021 to 2025Enrolled65ConditionsSmall Cell Lung CancerArmsAnlotinib Plus Penpulimab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Liang ZengEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Fang TianEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, China.
Cunji WangDepartment of Oncology, Hunan Provincial Hospital of Traditional Chinese Medicine, Zhuzhou 410013, China.
Qun ChenOncology Department, Fuzhou Pulmonary Hospital, Fuzhou 350008, China.
Wenjuan JiangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Juan LiangOncology Department, Yiyang Central Hospital, Yiyang 413099, China.
Yanming TanGenePlus-Shenzhen, Shenzhen 518000, China.
Huan YanEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, China.
Jiao HuangEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, China.
Chunhua ZhouDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Haiyan YangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Zhaohui RuanEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Third Xiangya Hospital, Central South University, Changsha 410000, China.
Zhe HuangEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, China.
Jiacheng DaiEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Yuanqing FengOncology Department, Xiangtan Central Hospital, Xiangtan 4111002, China.
Yi XiongDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Li LiuDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Chengzhi ZhouRespiratory Zone Five / Oncology Center Zone One, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510145, China.
Qinqin XuDepartment of Medical Oncology, Qinghai Provincial People's Hospital, Xining 810000, China.
Yue XieGenePlus-Shenzhen, Shenzhen 518000, China.
Chao ZhangGenePlus-Shenzhen, Shenzhen 518000, China.
Haoran GuoCentral Medical Center,Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing 211100, China.
Bing ZhangOncology Department, Yiyang Central Hospital, Yiyang 413099, China. Electronic address: 2558042026@qq.com.
Zhijun WuOncology Department, The First People's Hospital of Changde City, Changde 417500, China. Electronic address: 1056068115@qq.com.
Nong YangDepartment of Medical Oncology, Hunan Second People's Hospital, Changsha 410013, China. Electronic address: yangnong0217@163.com.
Yongchang ZhangEarly Clinical Trial Center, Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. Electronic address: zhangyongchang@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options are limited for patients with extensive-stage small cell lung cancer (ES-SCLC) after platinum-based therapy. This open-label, single-arm, multicenter phase 2 trial evaluates penpulimab plus anlotinib in 65 patients with first-line platinum-resistant ES-SCLC. The confirmed objective response rate by blinded independent central review is 41.5% (95% confidence interval [CI]: 29.2%-53.8%), and the disease control rate is 75.4% (95% CI: 64.6%-86.1%). Median progression-free survival and overall survival are 4.4 (95% CI: 3.5-5.3) and 10.5 (95% CI: 4.1-17.2) months, respectively. Grade ≥3 treatment-related adverse events occurred in 23.1% of patients, with no new safety signals. Exploratory circulating tumor DNA (ctDNA) analysis suggests that lower baseline maximum somatic allele frequency is associated with improved survival, and decreased T cell receptor clonal diversity is observed at disease progression. Penpulimab plus anlotinib shows promising antitumor activity with a manageable safety profile and may represent a potential second-line treatment option for platinum-resistant ES-SCLC. This study was registered at ClinicalTrials.gov (NCT05001971).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorIndolesLung NeoplasmsQuinolinesSmall Cell Lung CarcinomaAdultAgedAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedTreatment OutcomeanlotinibAntibodies, Monoclonal, HumanizedBiomarkers, TumorIndolespenpulimabQuinolinesanlotinibanti-angiogenesisbiomarkerscombination therapyPD-1 inhibitorpenpulimabsmall cell lung cancer

Identifiers

PMID42486095
PMCPMC13522778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.